MedPath

Feasibility of ultra high field 7.0 Tesla MRIfor the detection of breast cancer.

Completed
Conditions
Breast tumorBreast neoplasm
Registration Number
NL-OMON20303
Lead Sponsor
niversity Medical Center Utrecht (UMCU)Visiting address-----------------------Heidelberglaan 1003584 CX UtrechtThe NetherlandsPostal address---------------------Room E01.132PO Box 855003508 GA UtrechtThe NetherlandsPhone: +31 (0)88 75 555 55
Brief Summary

/A

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
20
Inclusion Criteria

1. 18 years or older;

2. Female patients;

Exclusion Criteria

1. Any prior surgery or radiotherapy to the ipsilateral breast;

2. Karnofsky score <= 70;

Study & Design

Study Type
Observational non invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The primary endpoint is the 7T detection rate of stage T1 breast cancer lesions in a cohort of women with BI-RADS 4c of higher lesion at mammography, ultrasound and/or lower field strength MRI.
Secondary Outcome Measures
NameTimeMethod
1. To assess the morphology of breast cancer at 7T as described according to the MRI BI-RADS lexicon;<br /><br>2. To assess the kinetics of lesion enhancement at 7T;<br /><br>3. To assess the correlation of 7T MRI lesion size and lesion size as determined by final pathological analysis. <br>
© Copyright 2025. All Rights Reserved by MedPath